Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 9c
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $35.54 million versus the consensus estimate of $24.51 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kepler Cheuvreux Downgrades Volkswagen AG (VOW:GR) (VWAGY) to Hold
- Rothschild Redburn Starts Terawulf Inc. (WULF) at Neutral
- Rothschild Redburn Starts Applied Digital (APLD) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
